Vaccinia complement control protein: multi-functional protein and a potential wonder drug
- PMID: 12734405
- DOI: 10.1007/BF02970146
Vaccinia complement control protein: multi-functional protein and a potential wonder drug
Abstract
Vaccinia virus complement control protein (VCP) was one of the first viral molecules demonstrated to have a role in blocking complement and hence in the evasion of host defense. Structurally it is very similar to the human C4b-BP and the other members of complement control protein. Functionally it is most similar to the CR1 protein. VCP blocks both major pathways of complement activation. The crystal structure of VCP was determined a little over a year ago and it is the only known structure of an intact and complete complement control protein. In addition to binding complement, VCP also binds to heparin. These two binding abilities can take place simultaneously and contribute to its many function and to its potential use in several inflammatory diseases, e.g. Alzheimer's disease (AD), CNS injury, xenotransplantation, etc. making it a truly fascinating molecule and potential drug.
Similar articles
-
Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP).Mol Immunol. 1999 Jul;36(10):685-97. doi: 10.1016/s0161-5890(99)00081-4. Mol Immunol. 1999. PMID: 10509819
-
Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense.J Virol. 2000 Jun;74(12):5659-66. doi: 10.1128/jvi.74.12.5659-5666.2000. J Virol. 2000. PMID: 10823874 Free PMC article.
-
Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance.Biochim Biophys Acta. 2003 Aug 21;1650(1-2):30-9. doi: 10.1016/s1570-9639(03)00189-4. Biochim Biophys Acta. 2003. PMID: 12922167
-
Exploring the potential benefits of vaccinia virus complement control protein in controlling complement activation in pathogenesis of the central nervous system diseases.Mol Immunol. 2014 Oct;61(2):204-9. doi: 10.1016/j.molimm.2014.06.022. Epub 2014 Jul 19. Mol Immunol. 2014. PMID: 25052409 Review.
-
Neuroprotection from complement-mediated inflammatory damage.Ann N Y Acad Sci. 2004 Dec;1035:147-64. doi: 10.1196/annals.1332.010. Ann N Y Acad Sci. 2004. PMID: 15681806 Review.
Cited by
-
The unique immune evasion mechanisms of the mpox virus and their implication for developing new vaccines and immunotherapies.Virol Sin. 2024 Oct;39(5):709-718. doi: 10.1016/j.virs.2024.08.008. Epub 2024 Aug 22. Virol Sin. 2024. PMID: 39181538 Free PMC article. Review.
-
Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood.Infect Immun. 2009 Feb;77(2):725-32. doi: 10.1128/IAI.01305-08. Epub 2008 Dec 1. Infect Immun. 2009. PMID: 19047409 Free PMC article.
-
Cross-species transmission and host range genes in poxviruses.Virol Sin. 2024 Apr;39(2):177-193. doi: 10.1016/j.virs.2024.01.007. Epub 2024 Jan 23. Virol Sin. 2024. PMID: 38272237 Free PMC article. Review.
-
Identification of complement regulatory domains in vaccinia virus complement control protein.J Virol. 2005 Oct;79(19):12382-93. doi: 10.1128/JVI.79.19.12382-12393.2005. J Virol. 2005. PMID: 16160165 Free PMC article.
-
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous